Floatz logo

Osimertinib

Advanced Solid Tumors Cancer

AbbVieSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Advanced Solid Tumors Cancer cohort.

Asset / SponsorPhaseRating
MAB HUMANIZED (IGG1) ANTI P43489 (TNR4_HUMAN) (ABBV368)
AbbVie
Phase 1CCC
Budigalimab
AbbVie
Phase 1CCC
gfh375
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2CC
Ndi-219216
Nimbus Wadjet, Inc.
Phase 1/2CC
Abbv-428
AbbVie
Phase 1CC

View all 20 →

Same molecule, other indications

Osimertinib is also rated in:

EGFR Exon 19 DeletionDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
EGFR Activating MutationDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →